


























Alzheimer’s disease (AD) is a chronic neuro-
degenerative disorder characterized by progressive 
cognitive decline and memory loss. Accumulation of β-
amyloid (Aβ) and tau protein are believed to be 
important pathological features of AD [1]. Results from 
a large number of studies suggest that neuro-
inflammation is a key contributor to neuronal loss in 
AD. Anti-inflammatory drugs, in particular non-
steroidal anti-inflammatory drugs (NSAIDs), seem to be 
beneficial in terms of slowing the development of AD, 
as shown by several epidemiological studies [2-4]. 
Inhibition of cyclooxygenase (COX) activity is the main 
mechanism of action of NSAIDs. Two COX isoforms, 
COX-1 and COX-2, have been identified. Clinical 
studies evaluating the effects of NSAIDs or COX-2 
selective inhibitors on AD have failed to show 
therapeutic efficacy. Some authors have suggested that 
the main reason for this is that COX-1 and COX-2 are 
involved in AD neuropathology in a preclinical stage of 
the disease. This explains the positive reports of the 
epidemiological studies and the negative findings in 
clinical trials with COX inhibitors [5, 6]. Long-term use 
o f  N S A I D s  m i g h t  r e d u c e  t h e  r i s k  o f  A D ,  i f  t h e  
treatment starts before the onset of AD dementia [7]. 
 
There is considerable debate on the relative contribution 
of each  COX  isoform to AD  pathology.  In AD  brains,  
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neuronal COX-2 levels have been found to be either 
elevated in early stages [8-10] or decreased in end-stage 
[11]. It is interesting to note that an upregulation in 
early AD and reduction of COX-2 in advanced AD 
correlates very nicely with the levels of prostaglandin 
E2 (PGE2) in the CSF, which are increased in subjects 
with mild memory impairment (probable AD diagnosis) 
and decreased with increasing severity of AD dementia 
[12, 13] . COX-2 is expressed in neurons, but not in 
astrocytes or microglia in AD brains [5]. Transgenic 
mice in which human COX-2 is overexpressed 
constitutively in neurons develop age-dependent 
cognitive deficits that are associated with a parallel age-
dependent increase in neuronal apoptosis and astrocytic 
activation [14]. Overexpression of COX-2 in APPswe-
PS1dE9 mice leads to age-dependent cognitive deficits 
in females but not male mice, without significantly 
affecting Aβ accumulation. The cognitive deficits in 
female COX-2/APPswe-PS1dE9 mice are reversed with 
administration of the COX-2 selective inhibitor 
celecoxib [15]. This suggests a sex-dimorphic 
involvement of COX-2 in AD neuropathology. 
Selective inhibition of COX-2, but not COX-1, 
prevented the suppression of hippocampal long-term 
potentiation (LTP) induced by Aβ1-42. The NSAIDs, 
ibuprofen and naproxen, and a selective COX-2 
inhibitor restored memory function in Tg2576 mice 
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expressing microglia surrounds amyloid plaques [17]. 
There is no evidence that COX-1 expression in 
microglia is changed in AD brain [5]. However, 
accumulation of COX-1-expressing microglia in AD 
could result in local increase in prostaglandin synthesis 
and oxidative stress.  
 
In a very recent article by Choi and Bosetti, published 
in the February issue of Aging, they report for the first 
time the effect of COX-1 gene deletion on the 
neurotoxicity associated with Aβ [18]. These data 
provide strong experimental evidence linking COX-1 
activity to neuronal loss following intracerebro-
ventricular administration of Aβ. Authors found a 
dramatic inflammatory response within the CA1 and 
CA3 areas of the hippocampus in 3-month-old wild-
type mice seven days after Aβ1-42 peptide injection. This 
neuroinflammatory response was characterized by the 
presence of Iba-1-positive activated microglia, 
increased GFAP-immunoreactive astrocytes, and 
elevated oxidative stress markers. Interestingly, COX-1 
deficient mice displayed a significant reduction in the 
number of activated microglia in the CA3 region of the 
hippocampus as well as in the number of GFAP-
positive reactive astrocytes, indicating that Aβ1-42 
injection induced less severe glial activation in COX-1 
knockout animals compared to wild-type control mice. 
In addition, COX-1 deficiency was associated with 
decreased oxidative damage, suggesting that enhanced 
COX-1 activity is a significant source of oxidative 
stress in Aβ-mediated neurotoxicity. Levels of PGE2, 
PGF2α and thromboxane B2 (TXB2) were significantly 
reduced in COX-1 null mice compared with wild-type 
controls. More importantly, COX-1 deletion resulted in 
reduced neuronal damage following Aβ1-42  admi-
nistration, as shown by a reduced number of Fluoro-
Jade B (FJB)-positive cells in the hippocampus. 
 
The classical view that COX-2 is more important than 
COX-1 in neuroinflammatory processes should be 
revisited. The data of Choi and Bosetti [18], together 
with findings from other studies [19-21] indicate that 
COX-1 is actively involved in brain injury induced by 
pro-inflammatory stimuli including Aβ, lipopolysac-
charide (LPS) and TNF-α. In some models of 
neuroinflammation, COX-2 deletion or pharmacological 
inhibition with selective agents exacerbate rather than 
reduce inflammation-related brain damage [22]. COX-1 
is prominently expressed by microglia [8, 17]. Due to 
the key role of microglia in neuroinflammation, it has 
been suggested that selective inhibition of COX-1, 
rather than COX-2, will be more effective in treating 
neuroinflammation and neurodegeneration [23].  
Reduction in cognitive decline in AD patients was 
observed in a 6-month, double-blinded, placebo-
controlled study with indomethacin, a non-selective, but 
a potent COX-1 inhibitor [24]. No beneficial effects 
were observed with the COX-2 selective inhibitors 
celecoxib and rofecoxib [25-29]. Based on these 
previous studies and their own data [18], Choi and 
Bosetti propose the intriguing hypothesis that the 
potential protective effects of NSAIDs in AD may be 
related to COX-1, but not COX-2 inhibition. In support 
of this notion, a previous study showed that neurons 
treated with COX-1 selective inhibitors are resistant to 
Aβ1-42  [30]. Moreover, COX-1 inhibition produced a 
profound inhibition of either LPS- or arachidonic acid-
induced PGE2 synthesis in human microglia [31].   
However, with the exception of one small pilot study 
[24], no therapeutic efficacy in AD clinical trials have 
been found with NSAIDs, including nonselective 
inhibitors such as naproxen and diclofenac, which 
inhibit both COX-1 and COX-2 [5, 26].  
 
A major limitation of chronic COX-1 inhibitor 
treatment of AD patients is the gastrointestinal toxicity, 
due to the suppression of COX-1-mediated production 
of protective prostaglandins. In the pilot clinical study 
showing beneficial effects of indomethacin in AD 
patients, the dropout rate in the indomethacin group was 
approximately 40%, mostly due to drug-related 
gastrointestinal adverse events  [24]. There is obviously 
a risk attached to taking any drug. However, clinical 
demonstration of a positive benefit/risk ratio of NSAIDs 
in AD patients is missing. It has been questioned 
whether anti-inflammatory interventions are really a 
viable or even preventive option for AD [6].  
 
It is still debatable whether targeting neuroinflammatory 
events in AD, primarily microglial activation, is a 
promising therapeutic option. In AD, microglia 
accumulate in senile plaques and may have a dual role, 
either digesting or contributing to the formation of Aβ 
plaques [1]. The idea of removal of senile plaque 
constituents by microglia was first proposed by Timmer 
in 1925, who suggested that these cells were mobilized 
to phagocytose toxic products and formed the core of 
senile plaques [32]. Clusters of microglial cells with 
rounded and phagocytic phenotypes are found in 
fibrillar Aβ deposits in the neocortex of AD brain [33]. 
In an elegant study published in Neuron, Simard and 
colleagues showed that it is the bone marrow-derived 
microglia, and not their counterparts resident in the 
brain, that have the ability to promote the clearance and 
phagocytosis of Aβ [34]. On the other hand, the 
production of inflammatory mediators by microglia 
might contribute to the formation of Aβ plaques [35]. 
Therefore, the specific role of these cells in the 
   
www.impactaging.com                  351                                     AGING, April 2009, Vol.1 No.4evolution of the senile plaques in AD is still under 
debate.  
 
Early accumulation of microglial cells in AD delays 
disease progression by facilitating clearance of Aβ 
before formation of senile plaques. However, persistent 
Aβ accumulation despite increasing microglial numbers 
indicate that the capacity of microglia to phagocytose 
Aβ may be impaired with age. A recent study indicates 
that the progression of Aβ plaque formation is 
associated with an aging-dependent dysfunction of 
microglia in the PS1-APP transgenic mice, an AD 
mouse model [36]. The number of senile-like plaques 
and microglia associated with these plaques are 
increased as the mice age. Microglia from old PS1-APP 
mice, but not from younger mice, have a decrease 
capacity to clear Aβ. This may be related to the 
increased production of proinflammatory mediators and 
to a downregulation of genes involved in Aβ removal 
[36]. These results illustrate the dichotomous role of 
microglia in AD pathology.  
  
Data from the report by Choi and Bosetti [18] are 
exciting and have potential clinical implications. This 
study will fuel future experimentation to elucidate the 
specific role of each COX isoform in neuro-
inflammation and neurodegenerative processes. It 
remains to be determined how COX-1 inhibition 
modifies the early beneficial function of activated 
microglia in Aβ clearance and whether COX-1 
inhibition is protective against neuronal loss in other 
models of AD such as the PS1-APP transgenic mice. Is 
COX-1 inhibition also protective in older animals and 
females? Future research will definitely provide 
answers to these questions. Elucidating the role of 
neuroinflammatory events in AD may provide oppor-
tunities toward the development of new therapeutic 
strategies to tackle neurodegeneration associated with 
AD and possibly other neurodegenerative disorders.  
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